Redesign Science is a platform biotech working at the interface of molecular dynamics and deep learning to create the first generative AI for drug discovery. Because we generate data from first-principles molecular simulation, we do not depend on pre-existing experimental data for new targets. Our platform identifies the best small molecule drug strategy for any target and develops novel chemical matter to modulate diverse target classes (e.g. PPIs, transcription factors, allosteric inhibitors, etc.). Redesign is advancing a pipeline of early stage small molecules for oncology and inflammatory diseases, and our approach is easily transferable to other indications and diverse target classes.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
We have novel, nanomolar chemical series against a well-validated target in the MAPK pathway
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
